STRAD-Binding Agents Stabilize LKB1 for Tumor Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively activate LKB1, a key tumor suppressor, in various cancers and metabolic disorders, limiting therapeutic options for cancer treatment and metabolic regulation.
Innovation Solution
Development of a compound that binds to the STRAD pseudokinase, specifically targeting the ATP binding pocket to stabilize and activate LKB1, thereby enhancing its activity and downstream signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to activate LKB1, then existing therapeutic approaches are maintained, but LKB1 activation is insufficient and therapeutic options are limited
Solution Approach 1:
The patent introduces STRAD pseudokinase as an intermediary mediator between the administered compound and LKB1 activation. The compound binds to STRAD pseudokinase, which then facilitates LKB1 activation through the LKB1-STRAD-MO25 trimer complex. This intermediary approach enables more reliable and versatile LKB1 activation compared to direct methods, resolving the contradiction between activation efficacy and therapeutic versatility.
2Productivity
If LKB1 activation is enhanced through STRAD pseudokinase binding, then tumor suppression and metabolic regulation improve, but the complexity of the therapeutic mechanism increases
Solution Approach 1:
The patent utilizes the cell's endogenous STRAD pseudokinase and LKB1-STRAD-MO25 complex as self-service components. The administered compound simply needs to bind to STRAD pseudokinase, after which the cell's own molecular machinery automatically carries out LKB1 activation and downstream signaling. This self-service approach enhances tumor suppression efficacy while minimizing the complexity burden on the therapeutic system.
Data Source
AI summary
Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.